STAAR Surgical (NASDAQ:STAA) Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. decreased its position in shares of STAAR Surgical (NASDAQ:STAA) by 6.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,022 shares of the medical instruments supplier’s stock after selling 1,570 shares during the quarter. Fox Run Management L.L.C.’s holdings in STAAR Surgical were worth $559,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Quarry LP acquired a new position in STAAR Surgical during the 3rd quarter valued at about $50,000. Quest Partners LLC acquired a new position in shares of STAAR Surgical during the third quarter worth approximately $128,000. KLP Kapitalforvaltning AS bought a new position in STAAR Surgical in the 4th quarter worth approximately $180,000. Larson Financial Group LLC increased its position in STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock valued at $181,000 after acquiring an additional 2,135 shares during the period. Finally, FMR LLC raised its stake in STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock valued at $263,000 after acquiring an additional 3,136 shares in the last quarter. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

STAAR Surgical stock opened at $17.77 on Tuesday. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The firm’s 50 day moving average price is $19.77 and its two-hundred day moving average price is $25.52. The firm has a market cap of $876.51 million, a price-to-earnings ratio of -43.34 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on STAA. Jefferies Financial Group cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Canaccord Genuity Group lowered their target price on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. William Blair lowered shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Mizuho cut shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. Finally, BTIG Research cut STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, STAAR Surgical currently has an average rating of “Hold” and a consensus price target of $25.29.

Insider Buying and Selling

In related news, major shareholder Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock in a transaction dated Wednesday, February 12th. The stock was acquired at an average cost of $14.96 per share, with a total value of $3,883,855.36. Following the completion of the acquisition, the insider now directly owns 11,137,623 shares in the company, valued at approximately $166,618,840.08. This trade represents a 2.39 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 1,036,187 shares of company stock worth $17,239,548 in the last three months. 1.00% of the stock is currently owned by insiders.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.